The European CyberKnife Center Munich is celebrating its 5,000th patient treatment using the CyberKnife® System

The European CyberKnife Center Munich is celebrating its 5,000th patient 
treatment using the CyberKnife® System 
Where experience and state-of-the-art technology meet 
SUNNYVALE, Calif., April 7, 2014 /CNW/ - Accuray Incorporated (Nasdaq: ARAY) 
announced today that the European CyberKnife Center Munich-Grosshadern (ECZM) 
has performed 5,000 CyberKnife® treatments since June 2005. The center uses a 
CyberKnife M6™ System from the latest generation series, the most advanced 
robotic radiosurgery system in the world. Patients of the center benefit from 
a treatment option that offers enhanced stereotactic radiosurgery/stereotactic 
body radiation therapy (SRS/SBRT): tumors are treated non-invasively with 
precisely delivered high doses of radiation. 
The European CyberKnife Center, in partnership with the University Hospital of 
Munich-Großhadern, offers almost 10 years of experience with this 
state-of-the-art technology. "The treatment with the CyberKnife System offers 
a number of benefits compared to surgery: no anesthesia, no pain and minimal 
side effects," explains Prof. Alexander Muacevic, who founded the treatment 
center together with his colleague Prof. Berndt Wowra in 2005. The CyberKnife 
System is used for tumors anywhere in the body. Prof. Muacevic added, "We 
treat brain tumors as well as tumors in the spine, the lung, the liver, and 
the prostate with good clinical outcomes. This remarkable technology is based 
on an integration of the latest developments in the field of image guidance, 
computer sciences and robotic radiation delivery." 
The CyberKnife System features a compact linear accelerator mounted on a 
robotic arm. It is the only system that automatically adjusts the beam 
delivery to motion during treatment in real-time. This precision is essential 
to deliver high doses to the target area while simultaneously minimizing 
radiation exposure to surrounding healthy tissue and organs. The CyberKnife M6 
System can deliver non-coplanar, non-isocentric beams from a wider number of 
angles around the patient, with the ability to follow tumors in real-time 
throughout the treatment. This provides clinicians the confidence to reduce 
margins for every disease that is treatable with the CyberKnife System. 
"Accuray is proud of the cooperation with the European CyberKnife Center.  We 
congratulate the European CyberKnife team on this tremendous achievement, and 
are pleased our precise, innovative tumor treatments are available to patients 
in such a highly experienced center," said Lionel Hadjadjeba, SVP Business 
International & GM EIMEA, Accuray International. 
About Accuray Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology 
company that develops, manufactures and sells precise, innovative treatment 
solutions that set the standard of care with the aim of helping patients live 
longer, better lives. The company's leading-edge technologies deliver the full 
range of radiation therapy and radiosurgery treatments. 
About the European CyberKnife Center, Germany Besides the clinical and 
scientific cooperation with the Neurosurgical Department and the Institute of 
Clinical Radiology of the University of Munich, the CyberKnife Center Munich 
collaborates internationally with colleagues around the world. Close 
partnerships exist with the University Hospital Charite Berlin 
( and the Stanford University, California/ USA. 
Furthermore a scientific partnership is maintained with the Institute of 
Robotics and Cognitive Systems of the University Lübeck (Director: Professor 
Dr. Schweikard) where essential parts of the CyberKnife System have been 
developed (navigation software). Via the most modern telecommunication systems 
special cases are discussed with other dedicated experts around the world. 
Also, scientific projects are conducted on an international basis.Being part 
of the Radiosurgery Society's ( Board of Directors we 
put great effort in the development of internationally appreciated standards 
for treatment, education and quality control. 
Safe Harbor Statement  Statements made in this press release that are not 
statements of historical fact are forward-looking statements and are subject 
to the "safe harbor" provisions of the Private Securities Litigation Reform 
Act of 1995. Forward-looking statements in this press release relate, but are 
not limited to, the level of development of new technologies, clinical 
experience, clinical applications, clinical results, patient experiences and 
outcomes, and the company's leadership position in radiation oncology 
innovation and technology. Forward-looking statements are subject to risks and 
uncertainties that could cause actual results to differ materially from 
expectations, including risks detailed under the heading "Risk Factors" in the 
company's report on Form 10-K filed on August 29, 2013, the company's report 
on Form 10-Q filed on February 7, 2014, and as updated periodically by the 
company's other filings. 
Forward-looking statements speak only as of the date the statements are made 
and are based on information available to the company at the time those 
statements are made and/or management's good faith belief as of that time with 
respect to future events. Accuray assumes no obligation to update 
forward-looking statements to reflect actual performance or results, changes 
in assumptions or changes in other factors affecting forward-looking 
information, except to the extent required by applicable securities laws. 
Accordingly, investors should not place undue reliance on any forward-looking 

SOURCE  Accuray Incorporated 
Sancie Nakarat, Sr Marketing Communications Manager, Europe, Tel + 33 (0) 1 55 
23 20 20,; Laura Scally, MSLGROUP, +1 (781) 684-0770, 
To view this news release in HTML formatting, please use the following URL: 
CO: Accuray Incorporated
ST: California
-0- Apr/07/2014 12:30 GMT
Press spacebar to pause and continue. Press esc to stop.